People who have Dementia report that their symptoms have decreased after taking an Nrf2 activator. Following the testimonials are current research articles that report new information about the cause of Dementia and how Nrf2 activators can be effective in treating it at the cellular level where it starts.
JOURNAL ARTICLES (from pubmed.gov)
On November 2, 2017, Dr. Lee reported in the Journal of Agricultural Food Chemistry that Alpha-linolenic acid had strong positive effects on protective mechanisms by reducing oxidative stress and improving cognitive ability. This may be a good candidate for prevention or treatment of neurodegenerative diseases such as Alzheimer’s. (see pubmed.gov, 29092397).
On Oct. 30, 2017, Dr. Wang from the Nankai University in Tianjin, China reminded the public that resveratrol, a natural herbal compound isolated from grapes, could alleviate the development and progression of Alzheimer’s Disease, and reported on his new studies that proved it. He reported that resveratrol stopped cell death and increased numbers of organelles in cells. Resveratrol reduced oxidative stress and reduced cell death. This may be a new targeted therapy to stop the neuronal damage induced by Alzheimer’s. (see pubmed.gov, 29097221).
On Oct. 17, 2017, Dr. Oguchi and others at Showa University, Tokyo, Japan reported their study that showed that Cilostazol significantly reduced the oxidative stress that is a characteristic of people with Alzheimer’s disease. Their study showed that it suppressed cell death and increased cell viability by upregulation of superoxide dismutase (SOD). This is the same thing that Nrf-2 activators do – they upregulate SOD and other natural body antioxidants, which in turn reduce the oxidative stress that is at the root cause of Alzheimer’s. (see pubmed.gov, 29089887).
JOURNAL ARTICLE (from pubmed.gov)
Neurochem Int. 2015 Feb 5. pii: S0197-0186(15)00020-0. doi: 10.1016/j.neuint.2015.01.008. [Epub ahead of print]
Glutathione transferases and neurodegenerative diseases.
There is substantial agreement that the unbalance between oxidant and antioxidant species may affect the onset and/or the course of a number of common diseases including Parkinson and Alzheimer diseases. Many studies suggest a crucial role for oxidative stress in the first phase of ageing, or in the pathogenesis of various diseases including neurological ones. Particularly, the role exerted by glutathione and glutathione-related enzymes (Glutathione Transferases) in the nervous system appears more relevant, being this latter tissue much more vulnerable to toxins and oxidative stress than other tissues such as liver, kidney or muscle. The present review addresses the question by focusing on the results obtained by specimens from patients or by in vitro studies using cells or animal models related to Parkinson and Alzheimer diseases. In general, there is association between glutathione depletion and Parkinson or Alzheimer disease. In addition, it was found a significant decrease of glutathione transferase activity in selected areas of brain and in ventricular cerebrospinal fluid. For some glutathione transferases genes there is also correlation between polymorphisms and onset/outcome of neurodegenerative diseases. Thus, there is a general agreement about the protective effect exerted by glutathione and glutathione transferases but no clear answer about the mechanisms underlying this crucial role in the insurgence of neurodegenerative diseases.
Copyright © 2015 Elsevier Ltd. All rights reserved.
[INTERPRETATION: Parkinson's, Alzheimer's, and other common diseases are caused by oxidative stress (cell destruction). Low levels of the body's own antioxidants (glutathione) are associated with these diseases. Scientists agree that glutathione protects against diseases.]